Title : Compassionate use of ruxolitinib in patients with SARS-Cov-2 infection not on mechanical ventilation: Short-term effects on inflammation and ventilation.

Pub. Date : 2021 May

PMID : 33403775






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In the 31 patients who received ruxolitinib symptoms improved (dyspnea scale) at day 7 in 25 out of 31 patients (80.6%); C-reactive protein decreased progressively from baseline (79.1+-73.4 mg/dl) to day15 (18.6+-33.2, p=0.022). ruxolitinib C-reactive protein Homo sapiens